Quantcast

Latest Biologic Stories

2014-04-09 08:29:57

DUBLIN, April 9, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/stldww/global_psoriasis) has announced the addition of the "Global Psoriasis Therapeutics Market" [http://www.researchandmarkets.com/research/stldww/global_psoriasis ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the...

2014-04-08 23:02:54

New research report “Biosimilar Index: Tracking the Global Biosimilar Pipeline” worked out by FirstWord is now available at MarketPublishers.com London, UK (PRWEB) April 08, 2014 At present, biosimilars and non-comparable biologics (NCBs) are being developed across thirteen discreet therapy areas. There exist around 40 biosimilar and NCB programmes currently in Phase III trials. Moreover, it is known that there are fifteen biosimilar and NCB versions of bevacizumab (Avastin, Roche)...

2014-04-08 12:31:33

ROCKVILLE, Md., April 8, 2014 /PRNewswire/ -- Biologics development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that Karen Hughes has joined the Omnia team as Senior Director of Quality Assurance and Quality Control. Over the course of her nearly 23 year career in quality assurance, she has held quality positions of increasing responsibility in the manufacturing of pioneering pharmaceutical and biologic products. Karen worked for...

2014-04-08 08:30:44

ST. LOUIS, April 8, 2014 /PRNewswire/ -- ISTO Technologies, Inc. ("ISTO," the "Company"), a privately-held regenerative medicine company applying its proprietary platform technologies to orthopedic and spine applications, has appointed Phillip W. Kuhn, a medical technology executive with over three decades of industry experience, as the Company's Chief Commercial Officer. In this newly created role, Mr. Kuhn will oversee ISTO's commercial strategy, including the execution of...

2014-04-07 08:31:02

CARLSBAD, Calif., April 7, 2014 /PRNewswire/ -- Advanced Biologics announced today that they will be showcasing their most recent peer-reviewed published data at the American Academy of Neurosurgeons (AANS) meeting this week in San Francisco, CA. In the study titled Clinical Evaluation of Allogeneic Growth Factor in Cervical Spine Fusion, a retrospective analysis was conducted of one hundred and forty consecutive patients (228 levels) that had undergone cervical spine fusions using...

2014-04-07 04:21:25

BREDA, The Netherlands and GHENT, Belgium, April 7, 2014 /PRNewswire/ -- New findings to be presented at the American Association for Cancer Research annual meeting arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody(TM) platform has identified four 'hotspots' on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET...

2014-04-03 16:23:53

AUSTIN, Texas, April 3, 2014 /PRNewswire/ -- XBiotech announced today that it acquired the patent estate of Strox Biopharmaceuticals relating to antibody therapies for methicillin resistant staphylococcus aureus (MRSA). XBiotech is developing next generation natural immune therapies to address serious and drug resistant bacterial infections. The in-licensed technology is reportedly intended to expand and strengthen XBiotech's position for its infectious disease product development...

2014-04-03 12:30:06

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013 The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical...

2014-04-03 08:29:54

Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued US Patent #8,685,897 broadly covering a novel approach to antibody humanization using somatic hypermutation. Leveraging key advantages of AnaptysBio's...

2014-04-03 08:29:16

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/m5wnkh/competitor ) has announced the addition of the "Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'karpos', fruit.
Related